|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
The discovery of incretins (including GLP-1 and GIP) provides a novel therapy for the treatment of diabetes.
|
31785994 |
2020 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
These data highlight intra-islet benefits of (D-Ala<sup>2</sup>)GIP, xenin-25[Lys<sup>13</sup>PAL] and (D-Ser<sup>2</sup>)-Oxm[Lys<sup>38</sup>PAL] in diabetes with beta-cell loss induced by STZ.
|
31738969 |
2020 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Also, attention was diverted away from GIP by the successful development of glucagon-like peptide-1 (GLP-1) receptor agonists, and a therapeutic strategy for GIP became uncertain when evidence emerged that both inhibition and enhancement of GIP action could prevent or reverse obese non-insulin dependent forms of diabetes in rodents.
|
31756366 |
2020 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
As such, blockade of GIP receptor (GIPR) action has been proposed as a means to counter insulin resistance, and improve metabolic status in obesity and related diabetes.
|
31733230 |
2020 |
|
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These studies highlight the clear, and persistent, metabolic advantages of sustained activation of GLP-1 receptors, alongside concurrent activation of related GIP and xenin cell signalling pathways, in diabetes.
|
31756326 |
2020 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
While GIP shares common actions on the pancreatic beta cell with glucagon-like peptide-1 (GLP-1), unlike GLP-1, GIP presents a complex target for the development of diabetes and obesity therapies due to its extra-pancreatic effects on fat mass.
|
31697967 |
2020 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Although GLP-1 and GIP both enhance insulin secretion and subsequently ameliorate postprandial glucose excursion, most research has focused on GLP-1R as a therapeutic target for type 2 diabetes.
|
30637966 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
We found altered gastrointestinal motility in dialysis patients, with higher gastric retention and prolonged gastric emptying, and higher total AUC of GIP and glucagon independent of the presence of diabetes or prediabetes.
|
30667131 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
DPP-4 (dipeptidyl peptidase-4) inhibitors (or "gliptins") represent a class of oral anti-hyperglycemic agents that inhibit the enzyme DPP-4, thus augmenting the biological activity of the "incretin" hormones (glucagon-like peptide-1 [GLP-1] and glucose-dependent insulinotropic polypeptide [GIP]) and restoring many of the pathophysiological problems of diabetes.
|
31366085 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Twenty patients of active acromegaly (10 each, with and without diabetes) underwent hyperinsulinemic euglycaemic clamp and mixed meal test, before and after surgery, to measure indices of IS, β-cell function, GIP, GLP-1 and glucagon response.
|
30948746 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
<b>Results</b>: Recent literature shows that GLP-1 and its agonists, DPP-4 inhibitors and combined GLP-1/GIP molecules are effective in partially or fully reversing the effects of neurotoxic compounds, neurovascular complications of diabetes, neuropathological changes related with Alzheimer's disease, Parkinson's disease or vascular occlusion.
|
30938196 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
The glucagon-like peptide-1 receptor (GLP-1R) agonist liraglutide is an incretin hormone mimetic used in the treatment of diabetes.
|
29947538 |
2018 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Novel dual GLP-1/GIP receptor agonists have been developed to treat diabetes, and they also show good neuroprotective effects that are superior to single GLP-1 analogues.
|
29402504 |
2018 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Combined modulation of peptide hormone receptors including, glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and xenin, have established benefits for the treatment of diabetes.
|
29412820 |
2018 |
|
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The results demonstrated that fasting blood glucose, triglyceride, total cholesterol and gastric inhibitory polypeptide levels in all treatment groups were significantly lower than those of the SO and DM groups.
|
29725390 |
2018 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Glucose-dependent insulinotropic polypeptide (GIP) is closely related to diabetes and obesity, both of which are confirmed to increase the risk of coronary artery disease (CAD).
|
29765988 |
2018 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Changes of gastric inhibitory polypeptide and glucagon-like peptide messenger RNAs in biopsy samples were positively correlated with endocrine pancreas function in 88 patients without treatment for diabetes (R = 0.4314, P = 0.0012; R = 0.4112, P = 0.0081).
|
29683968 |
2018 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, the IR in the intestinal epithelium plays important roles in intestinal gene expression, glucose uptake, and GIP production, which may contribute to pathophysiological changes in individuals with diabetes, metabolic syndrome, and other insulin-resistant states.
|
28096258 |
2017 |
|
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The effect of liraglutide (GLP-1 receptor agonist) administration on glucose tolerance, insulin release, and glucose-dependent insulinotropic polypeptide level was detected in a HFD-induced diabetes C57/BL6 mouse model.
|
28290604 |
2017 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
GLP-1 and GIP combination is suggested as a promising therapeutic strategy for treatment of obesity and diabetes.
|
28610922 |
2017 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Antagonizing the glucose-dependent insulinotropic polypeptide (GIP) receptor may open up new therapeutic modalities in the treatment of diabetes and obesity.
|
28055305 |
2017 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Dipeptidyl-peptidase 4 [DPP-4) has evolved into an important target in diabetes therapy due to its role in incretin hormone metabolism.
|
28213130 |
2017 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
We hypothesized that the bulbospinal neurons in the rostral ventrolateral medulla (RVLM) are affected by the levels of glucose, insulin, or incretins (glucagon like peptide-1 [GLP-1] or glucose-dependent insulinotropic peptide [GIP]) in patients with DM.
|
28062192 |
2017 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Within the pancreatic islet, IL-6 stimulates secretion of the prosurvival incretin hormone glucagon-like peptide 1 (GLP-1) by α cells and acts directly on β cells to stimulate insulin secretion <i>in vitro</i> Uncovering physiologic mechanisms promoting β-cell survival under conditions of inflammation and stress can identify important pathways for diabetes prevention and treatment.
|
28592636 |
2017 |
|
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition to these associations, higher levels of insulin, gastric inhibitory polypeptide, and pancreatic polypeptide remained significantly associated with self-reported diabetes with a false discovery rate <5%, indicating that the assay was able to detect markers associated with diabetes.
|
28753646 |
2017 |